Prostate cancer is one of the most common malignancies in men and arises from cells in the prostate gland, usually in the peripheral zone. Risk increases sharply with age and is influenced by genetic factors, family history, ethnicity, and lifestyle. Many tumors grow slowly and may never cause symptoms, while others are aggressive and can spread to lymph nodes, bones, and distant organs.

Screening focuses on prostate specific antigen (PSA) blood testing and digital rectal examination. Elevated PSA can indicate cancer but also benign conditions such as prostatitis or benign prostatic hyperplasia, so interpretation is nuanced. Research has refined PSA based tools, including age adjusted ranges, PSA velocity, and density, as well as the use of MRI and risk calculators to improve the decision to biopsy and to limit overdiagnosis.

Pathologists grade tumors using the Gleason system, now grouped into prognostic grade groups that correlate with outcomes. Localized disease is managed with options such as active surveillance, radical prostatectomy, and radiotherapy. Active surveillance has become a key strategy for low risk cases, using regular PSA testing, imaging, and repeat biopsies to avoid or delay treatment side effects while maintaining cancer control.

Advanced disease management includes androgen deprivation therapy, newer hormonal agents, chemotherapy, targeted therapies, and radiopharmaceuticals. Imaging advances such as multiparametric MRI and PSMA based positron emission tomography improve staging and detection of recurrence. Research continues on biomarkers, genomic profiling, and personalized treatment strategies to better distinguish indolent from aggressive cancers, aiming to maximize survival while minimizing overtreatment and impact on quality of life.